摘要
目的:观察中药KLW-1治疗恶性神经胶质瘤的临床疗效,为新药研发提供有效性依据。方法:回顾性分析2005-2007年在首都医科大学宣武医院行恶性神经胶质瘤(Ⅲ～Ⅳ级)切除术患者59例,将患者分为两组(KLW-1组和对照组),以1年,2年,3年的生存率、中位生存期为疗效指标,观察KLW-1的临床疗效,应用Kaplan-Meier法进行统计学分析。结果:KLW-1组的1年,2年,3年生存率分别为66.67%,41.67%和33.33%,中位生存期为17个月,对照组的1年,2年,3年生存率分别为52.17%,21.74%,13.04%,中位生存期为13个月,应用Kaplan-Meier法分析KLW-1组和对照组的生存曲线具有统计学意义(P<0.05)。结论:中药KLW-1可以延长恶性神经胶质瘤的生存时间,具有肯定疗效。
Objective： To evaluate the efficacy of KLW-1 in the treatment of human malignant glioma, and to provide scientific basis for research and development of new medicine. Methods： A total of 59 patients with malignant glioma, WHO stage Ⅲ～Ⅳ, underwent complete resection from Jan. 2005 to Jan. 2007 in XuanWu Hospital of Capital Medical University, were reviewed and analyzed. Patients were divided into KLW-1 and control groups. The efficacy was evaluated with the indexes, such as the overall 1-, 2- and 3-year survival rates and the median survival time. Kaplan-Meier method was used for statistical analysis. Results： The overall 1-, 2- and 3- year survival rates and the median survival time were 66.67% , 41.67% , 33.33% and 17 months in KLW-I group, 52. 17%, 21.74%, 13.04% and 13 months, respectively, in control group. Statistical analysis results showed that the survival curve was significantly better in KLW-1 group than in control group （P = 0. 035 9）. Conclusion： KLW-1 can prolong the life time in patients with malignant gliomas, and its efficacy is confirmable.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2011年第19期1894-1897,共4页
Chinese Journal of New Drugs
基金
北京市中医药科技项目资助(JJ2010-11)
北京市卫生系统高层次卫生技术人才培养计划学科骨干项目资助(2011-3-096)
